Access Pharmaceuticals, Inc. Stock OTC Bulletin Board
Equities
ACCP
US00431M3088
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
05-30 | Stifel Starts Abeona Therapeutics With Buy Rating, $21 Price Target | MT |
05-16 | Cantor Fitzgerald Adjusts Price Target on Abeona Therapeutics to $21 From $36, Maintains Overweight Rating | MT |
Sales 2024 * | - | Sales 2025 * | 16.54M 22.54M | Capitalization | 180M 246M |
---|---|---|---|---|---|
Net income 2024 * | -70M -95.38M | Net income 2025 * | -65M -88.57M | EV / Sales 2024 * | - |
Net cash position 2024 * | 66.3M 90.34M | Net Debt 2025 * | 7.4M 10.08M | EV / Sales 2025 * | 11.4 x |
P/E ratio 2024 * |
-2.39
x | P/E ratio 2025 * |
-2.85
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.62% |
Latest transcript on Access Pharmaceuticals, Inc.
Managers | Title | Age | Since |
---|---|---|---|
Vishwas Seshadri
CEO | Chief Executive Officer | 48 | 21-05-31 |
Michael Amoroso
CHM | Chairman | 46 | 20-07-08 |
Joseph Vazzano
DFI | Director of Finance/CFO | 40 | 22-03-13 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mark Alvino
BRD | Director/Board Member | 56 | 06-02-28 |
Faith Charles
BRD | Director/Board Member | 62 | 21-03-24 |
Leila Alland
BRD | Director/Board Member | 61 | 21-04-18 |
1st Jan change | Capi. | |
---|---|---|
+43.36% | 54.63B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- ABEO Stock
- ACCP Stock